effects of my decision with my physician. 
Protocol HNS 94-001 
REVISED 11/17/94 
Page A of 5 
In addition, I understand that the investigator may discontinue the clinical research 
study if, in the sole opinion and discretion of the investigator, the study or treatment 
offers me little or no future benefit, or the supply of medication ceases to be 
available or other causes prevent continuation of the clinical research study. The 
investigator will notify me should such circumstances arise and my physician will 
advise me about available treatments which may be of benefit at that time. 
I will be informed of any new findings developed during the course of this clinical 
research study which might be relevant to my willingness to continue participation in 
the study. 
9. I have been assured that confidentiality will be preserved except that qualified 
monitors from the Food and Drug Administration, Microbiological Associates, 
Magenta Corporation (manufacturers of the virus), and National Cancer Institute may 
review my records where appropriate and necessary. Qualified monitors shall 
include assignees authorized by the Surveillance Committee of this institution 
provided that confidentiality is assured and preserved. My name will not be revealed 
in any reports or publications resulting from this study, without my expressed 
consent. 
10. I have been informed that, should I suffer any injury as a result of participation in 
this research activity, reasonable medical facilities are available for treatment at this 
institution. I understand, however, that I cannot expect to receive any credit or 
reimbursement for expenses from this institution or any financial compensation from 
this institution for such injury. 
11. I have been informed that I should inquire of the attending physician whether or not 
there are any services, investigational agents or devices, and/or medications being 
offered by the sponsor of this clinical research project at a reduced cost or without 
cost. 
Costs related to my medical care will be covered by the Introgen Sponsored Research 
Agreement. Clarification of specific cost issues may be addressed in section 3 of this 
informed consent. I have been given the opportunity to discuss the expenses or costs 
associated with my participation in this research activity. 
12. It is possible that this research project will result in the development of beneficial 
treatments, devices, new drugs, or possible patentable procedures, in which event I 
understand that I cannot expect to receive any compensation or benefits from the 
subsequent use of information acquired and developed through my participation in 
this research project. 
13. I understand that refraining from breast feeding and practicing effective contraception 
is medically necessary and a prerequisite for my participation in this clinical research 
Recombinant DNA Research, Volume 20 
[665] 
